Pharmacy Times

JULY 2, 2025

In an interview with Pharmacy Times , LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, oncology clinical manager at Atrium Health Wake Forest Baptist in Winston-Salem, North Carolina, shares insights about the facility’s Wake Outpatient Transplant Program and highlights its positive impact on patient care outcomes.

Compounding Pharmacies 65

Compounding Pharmacies Hospitals Immunization Compounding 65

Pharmacy Times

JULY 3, 2025

In an interview with Pharmacy Times , LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, oncology clinical manager at Atrium Health Wake Forest Baptist in Winston-Salem, North Carolina, highlights the extensive role of pharmacists in the Wake Outpatient Transplant program.

Specialty Pharmacies 65

Specialty Pharmacies Compounding Pharmacies Hospitals Immunization 65

Hospital Pharmacy Europe

FEBRUARY 5, 2025

4,5 Thrombosis is a significant cause of morbidity and mortality in PNH, with patients exhibiting an increased risk of life-threatening thromboembolic events such as stroke, deep vein thrombosis and pulmonary embolism. 6,7 The chronic nature of PNH significantly affects patients quality of life and health outcomes. 9 Brodsky RA et al.

Clinic Management 52

Clinic Management Hospitals 52

PQA

JANUARY 13, 2023

As the market continues to demand specialization in drug distribution and clinical management of complex therapies, specialty pharmacy continues to evolve. PQA SAMs are members-only events. Speakers from Loma Linda University and Walgreens will discuss their services featured in the guide. Register today!

Specialty Pharmacies 52

Specialty Pharmacies Patient Care Clinic Management 52

Viseven

JANUARY 9, 2023

Did you know that communicative errors are a major contributing factor to hospital sentinel events? In this method, clinical personnel interacts with caregivers formally. The goal is to learn and write down up to five significant non-clinical management techniques and ideas for individualized care.

Communication 52

Communication Hospitals Clinic Management Patient Care 52

Hospital Pharmacy Europe

SEPTEMBER 24, 2024

Indeed, vutrisiran – a new drug for the treatment of amyloidosis – has been found to be effective in reducing mortality, cardiovascular events and markers of disease progression. In light of HELIOS-B trial results , as Professor Esther Gonzalez Lopez commented, for patients with amyloidosis the future is brighter.

Documentation 52

Documentation Hospitals Clinic Management Patient Care 52

Hospital Pharmacy Europe

NOVEMBER 4, 2024

Durvalumab is ‘promising step forward’ The latest approval from the MHRA is based on positive data from the AEGEAN Phase III trial in rNSCLC , which showed that durvalumab-based treatment before and after surgery reduced the risk of recurrence, progression events or death by 32% versus neoadjuvant chemotherapy alone.

Chemotherapy 52

Chemotherapy Patient Care Clinic Management Hospitals 52